Cerus Corporation

CERS Healthcare Medical Devices

In the quarter to June 2026, revenue grew 5.28%, EPS grew 50.3%, free cash flow fell 20.9% and total debt fell 23.5%, each against the same quarter a year earlier.

2.20 0.06 −2.65%
Market cap
$455.5M
P/E
0.0×
Fwd P/E
−81.3×
Dividend yield
—
F-score
5/9
Altman Z
−4.00
Beneish M
−2.87
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
0.00 0.00 0.00 0.00

+8 more quarters

P/S ratio
2.36 1.44 1.68 1.35
P/FCF ratio
0.00 0.00 354.35 1,815.53
P/Operating CF
(220.09) (115.89) 63.33 158.28
P/B ratio
8.28 5.17 6.04 4.90
EV/Sales
2.40 1.46 1.68 1.38
EV/EBITDA
9,004.57 0.00 0.00 0.00
EV/FCF
(324.93) (293.71) 355.26 1,853.58
Current Ratio
1.83 1.63 1.73 1.89
Net Debt/EBITDA
(6.19) 47.38 (4.07) 3.95
Debt/Equity
0.92 1.24 1.29 1.36
Earnings Yield
(1.20%) (2.75%) (3.89%) (5.25%)
Free Cash Flow Yield
(0.31%) (0.34%) 0.28% 0.06%
Free Cash Flow per Share
(0.02) (0.02) 0.03 0.00
Book value per Share
0.35 0.35 0.34 0.32
Free Cash Flow
(3.53) (3.28) 4.89 0.09
EV/EBIT
0.00 0.00 0.00 0.00
Other line items

Show all line items

Columns are period end dates